PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
On March 17th, 2011, the European Commission issued a marketing authorization valid
throughout the European Union for Eribulin mesylate (Halaven; Eisai Limited), for the
treatment of patients with locally advanced or metastatic breast cancer who have progressed
after at least two chemotherapic regimens for advanced disease.
As the use of Eribulin will be widespread in this tumor setting, a better knowledge of its
safety profile outside clinical trials is warranted.
Indeed the possibility to select patients at risk for developing Eribulin-induced neuropathy,
will allow the exclusion from these treatment of those patients harbouring the specific
single nucleotide polymorphism (SNP). Given that Eribulin toxicity often results in treatment
discontinuation, the ability to anticipate which patients will experience severe toxicity
could allow for either early intervention or even possibly for prophylactic therapy, or for
selection of the patients to be treated.
Phase:
Phase 4
Details
Lead Sponsor:
Oncologia Medica dell'Ospedale Fatebenefratelli
Collaborator:
Mario Negri Institute for Pharmacological Research